# Mifepristone (RU-486) in Androgen Independent Prostate Cancer

> **NCT00140478** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 48 (estimated)

## Conditions studied

- Prostate Cancer
- Adenocarcinoma of Prostate

## Interventions

- **DRUG:** Mifepristone

## Key facts

- **NCT ID:** NCT00140478
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2006-06
- **Final completion:** 2008-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2009-12-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00140478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00140478, "Mifepristone (RU-486) in Androgen Independent Prostate Cancer". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00140478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*